Regeneron Pharmaceuticals, Inc. (REGN) Stock

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc. is led by CEO Leonard S. Schleifer, employs 15,158 people, headquartered in Tarrytown, US, publicly traded since 1991.

Regeneron Pharmaceuticals, Inc. (REGN) stock trades at $695.42 with a market capitalization of $71.64B. The stock is valued at a price-to-earnings (P/E) ratio of 17.44, price-to-book of 2.35, price-to-sales of 4.24. Over the past 52 weeks the stock has ranged between $476.49 and $821.11, and currently trades 15.3% below its 52-week high. It pays a dividend yielding 0.59%.

On profitability, Regeneron Pharmaceuticals, Inc. generates a return on equity (ROE) of 14.55%, above the typical market average, return on capital employed of 11.45%, an operating margin of 24.95%, a net profit margin of 29.65%.

In its most recent fiscal year, Regeneron Pharmaceuticals, Inc. reported annual revenue of $14.3B, net profit of $4.5B, revenue has compounded at 11.0% a year over the last five years, profit at 5.1% a year.

The balance sheet shows a debt-to-equity ratio of 0.09 — a conservative balance sheet with little leverage risk, a current ratio of 4.13, total assets of $40.6B, $3.1B in cash and equivalents.

REGN has an average daily trading volume of 997,120 shares, a beta of 0.24 (less volatile than the overall market).

Official website: www.regeneron.com